Oric Shares Slide After Rinzimetostat Data Mirrors Competitor Performance
Oric Pharmaceuticals saw its shares tumble after releasing dose-optimization data for 400 mg rinzimetostat paired with darolutamide in metastatic castration-resistant prostate cancer. The study's efficacy metrics were broadly in line with those reported for a competing regimen, drawing a range of analyst responses and leaving the company focused on…